Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
Interferon beta is prescribed for people with multiple sclerosis in an attempt to reduce the number of relapses occurring and to slow progression of disability. The current cost of the subsidy provided by PHARMAC for this drug is over NZ$5 million annually and is likely to rise. The history of funding decisions for interferon beta, the evidence for cost-effectiveness of the drug, and other possible ways of improving outcomes for people with multiple sclerosis other than this particular pharmaceutical subsidy are considered in this article. The authors conclude that the evidence for cost-effectiveness of interferon beta is not compelling, and other options need to be considered in an integrated package of health services for all people with MS in New Zealand.
McNaughton
Harry
H
Stroke/Rehabilitation Research, Medical Research Institute of New Zealand, Wellington. harry.mcnaughton@mrinz.ac.nz
Kayes
Nicola
N
McPherson
Kathryn
K
D000276:Adjuvants, Immunologic / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004335:Drug and Narcotic Control; D006801:Humans; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009313:National Health Programs / Q000191:economics; D009520:New Zealand; D011057:Politics; D018570:Risk Assessment; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016899:Interferon-beta